Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics of colorectal cancer patients with liver metastases according to preoperative chemotherapy

From: Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

Variable Non-targeted therapy (n = 114) Bev-combined therapy (n = 22) Cet-combined therapy (n = 23)
Sex
 Man 72 (63.2) 14 (63.6) 15 (65.2)
 Woman 42 (36.8) 8 (36.4) 8 (34.8)
Primary tumor site
 Right side 18 (15.8) 7 (31.8) 4 (17.4)
 Left side 96 (84.2) 15 (68.2) 19 (82.6)
Primary tumor grade
 G1–2 84 (73.7) 18 (81.8) 16 (69.6)
 G3 30 (26.3) 4 (18.2) 7 (30.4)
Histological subtype
 Non-mucinous 102 (89.5) 20 (90.9) 20 (87.0)
 Mucinous 12 (10.5) 2 (9.1) 3 (13.0)
Primary tumor pT categorya
 pT1–2 11 (9.6) 1 (4.5) 2 (8.7)
 pT3–4 103 (90.4) 21 (95.5) 21 (91.3)
Primary tumor pN categorya
 pN0 57 (50.0) 12 (54.5) 8 (34.8)
 pN1-2 57 (50.0) 10 (45.5) 15 (65.2)
Preoperative CEA level
 ≤ 5 ng/mL 45 (39.5) 7 (31.8) 9 (39.1)
 > 5 ng/mL 69 (60.5) 15 (68.2) 14 (60.9)
Metastasis presentation
 Synchronous 92 (80.7) 18 (81.8) 16 (69.6)
 Metachronous 22 (19.3) 4 (18.2) 7 (30.4)
Number of metastases per patientb 3 (1–32) 3 (1–14) 6 (1–15)
Resection status of liver metastases
 R0 88 (77.2) 16 (72.7) 15 (65.2)
 R1–2 26 (22.8) 6 (27.2) 8 (34.7)
Cycles of preoperative chemotherapyb 4 (2–12) 6 (3–11) 4 (2–8)
Duration of preoperative chemotherapyc
 Short duration 58 (50.9) 8 (36.4) 11 (47.8)
 Long duration 56 (49.1) 14 (63.6) 12 (52.2)
Chemotherapy backbone
 Oxa-based 83 (72.8) 13 (59.1) 5 (21.7)
 Iri-based 26 (22.8) 9 (40.9) 17 (73.9)
 Oxa + Iri-based 3 (2.6) 0 (0.0) 1 (4.3)
 Fluoropyrimidine only 2 (1.8) 0 (0.0) 0 (0.0)
Postoperative chemotherapy
 Yes 70 (61.4) 15 (68.2) 14 (60.9)
 No 44 (38.6) 7 (31.8) 9 (39.1)
Responsed
 PR 39 (36.4) 14 (63.6) 17 (73.9)
 SD 47 (43.9) 8 (36.4) 6 (26.1)
 PD 21 (19.6) 0 (0.0) 0 (0.0)
TRGe
 1–2 32 (28.1) 8 (36.4) 4 (17.4)
 3 39 (34.2) 7 (31.8) 10 (43.5)
 4–5 43 (37.7) 7 (31.8) 9 (39.1)
  1. Bev bevacizumab, Cet cetuximab, CEA carcinoembryonic antigen, Oxa oxaliplatin, Iri irinotecan, PR partial response, SD stable disease, PD progression disease, TRG tumor regression grade
  2. a According to the Union for International Cancer Control (UICC) staging system (7th edition)
  3. b These data are presented as median followed by range in parentheses; others are presented as number of patients followed by percentages in parentheses
  4. c Short duration of preoperative chemotherapy: ≤ 4 cycles for 2-week regimens or ≤ 3 cycles for 3-week regimens; long duration of preoperative chemotherapy: > 4 cycles for 2-week regimens or > 3 cycles for 3-week regimens
  5. d Because the initial computed tomography or magnetic resonance imaging was performed in other hospitals, 7 of 114 patients who received preoperative chemotherapy without targeted therapy were not evaluable for radiologic response
  6. e TRG was evaluated based on the patient-related analysis